Table 1.

Nanotechnology products under clinical evaluation for melanoma [122].

Product	Description	Phase	Recruitment	Trial Number
TREATMENT
Abraxane (Celgene)	Albumin-bound paclitaxel	Phase III, monotherapy	Completed	NCT00864253 (Metastatic Melanoma)
		Phase II, monotherapy	Completed	NCT00093119 (Metastatic Melanoma)
		Phase II, monotherapy	Completed	NCT00081042 (Metastatic Melanoma)
		Phase II, monotherapy	Completed	NCT00738361 (Intraocular Melanoma)
		Phase I, Hepatic Arterial Infusion	Completed	NCT00833807 (Liver Metastasis)
		Phase II, in combination with ipilimumab	Completed	NCT01827111 (Metastatic Melanoma)
		Phase II, in combination with Bevacizumab	Completed	NCT00462423 (Metastatic Melanoma)
		Phase II, in combination with Bevacizumab o ipilimumab	Completed	NCT02158520 (Metastatic Melanoma)
		Phase II, in combination with rituximab	Recruiting	NCT02142335 (Metastatic Melanoma)
		Phase I, in combination with cisplatin, Temodar (temozolomide), interferon alfa-2b and interleukin-2 (IL-2)	Completed	NCT00970996 (Metastatic Melanoma)
		Phase II, in combination with sorafenib	Completed	NCT00483301 (Metastatic Melanoma)
		Phase II, in combination with carboplatin	Completed	NCT00404235 (Metastatic Melanoma)
Marqibo (Spectrum)	Liposomal vincristine (non-PEGylated)	Phase I/II, monotherapy	Completed	NCT00145041 (Metastatic Melanoma)
		Phase II, monotherapy	Completed	NCT00506142 (Metastatic Melanoma)
2B3-101	Doxorubicin glutathione-pegylated liposomes	Phase I/II, monotherapy or in combination with trastuzumab	Completed	NCT01386580 (Metastatic Melanoma)
IMAGING
124I-cRGDY-PEG-dots	Silica nanoparticles with an NIR fluorophore, PEG coating and a 124I radiolabeled cRGDY targeting peptide	Phase I/II	Recruiting	NCT02106598 (Head/Neck Melanoma)
CANCER VACCINE
Lipo-MERIT (Biontech RNA Pharmaceuticals)	Four naked RNA-drug products formulated with liposomes	Phase I	Active, not recruiting	NCT02410733 (Malignant Melanoma)

Abbreviations: NIR: Near Infra-Red; PEG: polyethylene glycol; RNA: ribonucleic acid.